Immune system activation follows inflammation in unstable angina: pathogenetic implications  by Caligiuri, Giuseppina et al.
UNSTABLE ANGINA
Immune System Activation Follows Inflammation in Unstable Angina:
Pathogenetic Implications
GIUSEPPINA CALIGIURI, MD, GIOVANNA LIUZZO, MD, LUIGI M. BIASUCCI, MD, FACC,
ATTILIO MASERI, MD, FACC
Rome, Italy
Objectives. The aim of this study was to assess the relations
between inflammation, specific immune response and clinical
course in unstable angina (UA).
Background. Several studies suggest that either inflammation
and/or T-cell activation might have a pathogenetic role in UA, but
neither their potential reciprocal connection nor their relation to
the clinical course is known.
Methods. Serum levels of C-reactive protein (CRP) (inflamma-
tion), IgG, IgA, IgM, C3, C4 (humoral immunity), IL-2 and the
percentage of CD41, CD81 and CD31/DR1 T-cells (cell-
mediated immunity) were measured in 35 patients with UA and 35
patients with chronic stable angina (CSA) during a period of 6
months.
Results. The CRP levels and the main specific immune markers
(CD41 and CD31/DR1 cells, IL-2 and IgM) were higher in
unstable than in stable angina. In UA, the serum levels of IgM and
IL-2 and the percentage of double positive CD31/DR1 signifi-
cantly increased at 7 to 15 days, and returned to baseline at 6
months. The increment of circulating activated T cells (CD31/
DR1) in UA was inversely related to the admission levels of CRP
(r 5 20.63, p 5 0.003) and associated with a better outcome.
Conclusions. Our data suggest that the inflammatory compo-
nent systemically detectable in UA may be antigen-related and
that the magnitude of the immune response correlates with the
clinical outcome of instability.
(J Am Coll Cardiol 1998;32:1295–304)
©1998 by the American College of Cardiology
Systemic levels of inflammatory markers are frequently ele-
vated and associated with a worse prognosis in unstable angina
(UA) (1–3). Similarly, inflammatory cells are frequently acti-
vated in UA (4,5) and are especially abundant in the shoulder
region of coronary plaques (6) where they can play a key role
in plaque disruption (7) and thrombosis (8,9). Although these
findings strongly suggest that inflammation may have an im-
portant role in the pathogenesis of UA, the possible triggers of
this inflammatory response remain unclear. Recently, we have
demonstrated that neither clot system activation (10) nor
ischemia-reperfusion injury (11) are sufficient to elicit the
acute phase response observed in UA patients. Interestingly,
activated T lymphocytes are frequently found in peripheral
blood (12,13) and in the coronary plaques (8,9,14) of patients
with acute coronary syndromes. Thus, we reasoned that anti-
genic inflammatory stimuli might trigger both inflammation
and activation of the immune system in UA. To this end, we
correlated the time course of inflammatory markers and
immune system activation with disease progression in 35
patients with UA, either in the acute phase and during a
6-month follow-up after stabilization of symptoms, by measur-
ing serum levels of C-reactive protein (CRP) (as a marker of
inflammation), IgG, IgA, IgM, C3 and C4 (as markers of
humoral immunity) and the prevalence of circulating CD31/
DR1 cells (i.e., activated T lymphocytes) and serum levels of
interleukin (IL)-2 (as markers of cell-mediated immunity). The
same protocol was also applied to 35 patients with CSA serving
as control.
Methods
Patient population. Group A. Only patients with docu-
mented severe UA (15) of recent onset (,10 days before
admission) were admitted to the study as UA (n 5 35). All
patients had at least two episodes of rest angina or one episode
lasting more than 20 mins, during the last 24 h, accompanied
by transient ischemic ST-segment changes and no detectable
rise in creatine kinase-MB levels or troponin T levels (to
exclude micronecrosis, only patients with less than 0.2 mg/L
were included in the study). Full medical therapy, including
beta-adrenergic blocking agents and/or calcium antagonists,
low-dose aspirin and continuous i.v. infusion of nitrates and
heparin, was introduced on admission, and continuous electro-
cardiogram (ECG) telemetry monitoring was applied to all
patients during their stay in our coronary care unit. Patients
with less than one further ischemic episode after 48 h of full
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medical therapy were assigned to group A1 (n 5 19) while
patients with more than two unstable ischemic episodes (either
symptomatic or asymptomatic), after 48 h of full medical
therapy were assigned to group A2 (n 5 16, Braunwald class 3,
high risk).
Group B. As controls we studied 35 patients with exclu-
sively effort-related angina, stable for at least 12 months, with
a positive exercise stress test and at least one coronary stenosis
detected at angiography (.75% reduction of lumen diameter).
All patients were on low-dose aspirin and various combina-
tions of nitrates, beta-blockers and/or calcium antagonists.
This group also was subsequently split in two, according to the
clinical outcome. Group B1 included 20 patients with angina
Canadian Class I and II, who were discharged on medical
treatment only, while group B2 included 15 patients with
angina Canadian class III, who underwent elective coronary
revascularization.
Exclusion criteria. The exclusion criteria included evidence
of recent infectious disease, erythrocyte sedimentation rate
.20 mm/h, fever, immunosuppressive drug therapy, immuno-
logic disorders, known or suspected neoplastic diseases, con-
gestive heart failure, valvular heart disease, evidence of left
ventricular aneurysm, recent (,3 months) major trauma,
surgery, myocardial infarction or coronary revascularization
(coronary angioplasty or bypass surgery). All patients gave
their written informed consent to participate in the study,
which was approved by the Ethics Committee of our institu-
tion.
Sampling protocol. During an antigen-directed immune
response, the immune markers show a transient increase
starting from day 5, reach a plateau at day 7 through day 15
and then gradually decrease, returning to baseline at day 28
(16). The time course of immunologic and inflammatory
markers shows a transient reduction of the former and an
increase of the latter during the first 48 h after a surgical
procedure, with complete normalization at 7 days (17). Thus,
in patients with UA, blood samples were taken: 1) as close as
possible to the onset of the unstable phase and within 24 h of
an episode of rest angina (sample 1); 2) between 7 and 15 days
Figure 1. CRP levels were significantly higher on admission in group
A2 (25 mg/L, p , 0.0001) than in group A1 (4.5 mg/L) and groups B1
and B2 (3.3 and 2 mg/L respectively). The high CRP levels significantly
decreased in group A2 to 7.8, 0.2 to 32.2 mg/l in sample 2 and to 6.8,
0.2 to 26.5 mg/l in sample 3 (p , 0.0001 vs. sample 1). In control groups
B1 and B2, CRP levels were lower than in unstable angina groups (A1
and A2, p , 0.0001) and did not change during the study. The x-axis
represents the time of sampling: 1 5 admission; 2 5 after 7 to 15 days;
3 5 after 6 months; A1 5 resolving UA, n 5 19; A2 5 refractory UA,
n 5 16; B1 5 stable angina, Canadian class I to II, n 5 20; B2 5 stable
angina, Canadian class III to IV, n 5 15.
Abbreviations and Acronyms
Cp 5 Chlamydia pneumoniae
CRP 5 C-reactive protein
CSA 5 chronic stable angina
IL 5 interleukin
UA 5 unstable angina
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after the last ischemic episode and/or coronary revasculariza-
tion (sample 2); and 3) at 6 months follow-up (sample 3). In
patients with chronic stable angina (CSA) blood samples were
taken 1) on admission (sample 1); 2) between days 7 and 15
after the first sample and/or coronary revascularization (sam-
ple 2); and 3) at 6 months (sample 3). Each sample consisted
of 10 ml of blood obtained from a peripheral vein; an aliquot
of 3.5 ml was collected in tubes containing EDTA (1.5 ml) and
immediately analyzed by flow-cytofluorimetry. The remaining
blood was collected in plain plastic tubes and allowed to
coagulate for 1 h at room temperature. After clot formation,
the serum was collected in 200 ml aliquots and stored at 270°C
until analysis.
Sample analysis. Serum. C-reactive protein was measured
by an automated monoclonal antibody solid phase sandwich
enzyme immunoassay on the Abbott IMx instrument (Abbott
Laboratories, Chicago, Illinois). Immunoglobulins and com-
plement fractions were measured by nephelometry. Specific
IgG and IgM titres for Chlamydia pneumoniae (Cp) were
assessed by microimmunofluorescence assay, as previously
described (18). Interleukin-2 levels were measured by a
double-antibody sandwich technique (ELISA, CABRU, Milan,
Italy). Lymphocyte subpopulations were assessed by staining
fresh whole blood (EDTA) with the following fluorescein
isothyocianate (FITC) or phycoerythrin (PE) conjugated
monoclonal antibodies: anti-Leu-4 (CD3), anti-Leu-3a (CD4),
anti-Leu-2a (CD8), anti-Leu 12 (CD19) and anti-HLA-DR.
Leuco GATE-TM (CD45/CD14) was used to assess purity and
recovery inside the lymphocyte gate; FITC conjugated IgG1
and PE conjugated IgG2a were used to detect nonspecific
antibody binding (Becton Dickinson, California). The stained
samples were then treated with a lysing solution (Ortho-
immune Lysing Reagent, Ortho Diagnostic Systems, Raritan,
New Jersey) to lyse erythrocytes and washed prior to flow
cytometric analysis. The percentage of fluorescent positive cell
was determined using a FACscan flow-cytometer. As CD31/
DR1 double positive cells represent a very small proportion of
all leukocytes, in all experiments a minimum of 20,000 events
was acquired in the lymphocyte gate. Analysis was performed
using a commercially available software (LysYs II, Becton
Dickinson).
Statistical analysis. Data were analyzed by two-factor
(group and time) analysis of variance using the Statview 4.1
software (Abacus Concept Inc., Berkeley, California). Sheffe’s
test was used to identify significant differences between means
(group and/or time). Correlation between variables were as-
sessed by Spearman’s rank correlation. Prevalence of specific
Cp antibody titres in the study population was analyzed using
the Chi-squared test. A p value ,0.05 was considered statisti-
cally significant. In the box plot charts (Figs. 1 through 5), the
top, bottom and line through the middle of the box correspond
to the 75th percentile (top quartile), 25th percentile (bottom
quartile) and 50th percentile (median) respectively. The whis-
Figure 2. Total IgM serum levels were higher in unstable groups A1
and A2 than in stable angina groups B1 and B2 (p , 0.0001) and
showed a transient increase at sample 2 (p , 0.001 vs. sample 1 and
p , 0.05 vs. sample 3) that was not detectable in the controls. The
increment of IgM was significantly greater in group A1 (favorable
outcome) than in group A2 (p , 0.05).
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kers extend from the 10th percentile (bottom decile) to the
90th percentile (top decile).
Results
White blood cell count, percentages of total, CD19, CD3
and DR single positive lymphocytes, neutrophils, monocytes,
basophils and eosinophils, and serum protein levels did not
differ in any of the four subgroups throughout the study (data
not shown). The number of diseased coronary vessels, blood
cholesterol levels, blood pressure, cigarette smoking, diabetes
and familiarity for ischemic heart disease were all similar in the
four subgroups (data not shown).
Inflammation and immune system activation in acute UA
as compared with CSA. Data (median and range) are shown
in Table 1. Group A (UA) had significant higher admission
CRP serum levels and percentage of circulating T-helper
(CD41) cells than group B (CSA, p , 0.0001 and p , 0.01,
respectively) and had also less circulating T-suppressor
(CD81) cells than group B (p , 0.0001). Although being
similar on admission, the time course of IgM (p , 0.001), IL-2
(p , 0.0001) and CD31/DR1 (p , 0.0001) values showed a
significant and transient increase at sample 2 only in group A.
Conversely, CRP levels decreased in the follow-up (p ,
0.0001). In group B, none of the inflammatory/immune mark-
ers showed any variation during the study period. Specific IgM
titres for Cp were below the detectable limit in all patients.
Specific IgG for Cp were found in more than 60% in both
groups A and B (Table 2) and were stable over time (data not
Figure 3. The proportion of activated T cells (CD31/DR1) was similar
in unstable and stable angina groups on admission (sample 1), but was
transiently and significantly increased at sample 2 in group A and not
in group B (p , 0.0001). Group A1 (favorable outcome) showed a
more dramatic transient increase in activated T cells than group A2
(less favorable outcome): they were 6 (2 to 8) % in sample 1, increased
up to 20 (7 to 31) % at sample 2 (p , 0.0001) and returned to 5 (2 to
15) % at sample 3 (p , 0.0001 vs. sample 2, p 5 NS vs. sample 1). No
time variation was detectable in controls. The x-axis represents the
time of sampling: 1 5 admission; 2 5 after 7 to 15 days; 3 5 after 6
months; A1 5 resolving UA, n 5 19; A2 5 refractory UA, n 5 16; B1 5
stable angina, Canadian class I to II, n 5 20; B2 5 stable angina,
Canadian class III to IV, n 5 15.
Figure 4. The increment in CD31/DR1 (activated T) cells was signif-
icantly greater in case of favorable outcome (group A1, median
increase 250%) than in case of medical therapy failure in UA (group
A2, median increase 30%, p , 0.0001).
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shown). Of interest, the highest titres were detected in group B
even though seropositive patients tended to be more fre-
quently found in group A (p 5 0.09).
Relation between grade of inflammatory/immune responses
and the clinical outcome in UA and CSA. Data (median and
range) are shown in Table 3. Patients with persistent, severe
UA (group A2) had significantly higher CRP levels than
patients with treatment-responsive UA (group A1, p , 0.0001
vs. A2, Fig. 1). Conversely, the IgM levels increase was higher
in group A1 (p , 0.05, Fig. 2) and the percentage of activated
T cells (CD31/DR1) dramatically increased at sample 2 only
in group A1 (p , 0.0001 in sample 2 vs. samples 1 and 3, Fig.
3). Accordingly, highest titres of specific IgG for Cp were
significantly more frequent in group A1 than in A2 (p ,
0.0001, Table 2).
The levels of IL-2 were also transiently increased in UA as
compared to CSA (p , 0.0001, Table 1), but the increment was
similar in groups A1 and A2 (Fig. 5) and also the percentage of
CD41 and CD81 cells, in spite of being different in unstable
as compared to stable angina, did not show any relation neither
to the onset nor to the clinical evolution of instability and
remained unchanged during the study in both groups A1 and
A2. Interestingly, in group A the increment in the percentage
of CD31/DR1 cells was inversely related to the waxing UA
phase levels of CRP (Spearman’s rank correlation, r 5 20.63,
p 5 0.0003, Fig. 6). A more severe disease in CSA (group B2)
was associated with higher percentage of circulating CD31/
DR1 cells (p , 0.05 vs. group B1) but, at variance with group
A1, activated T cells did not show any further variation during
the study period in group B2 (Fig. 3).
Discussion
Our findings show that in UA a transient specific immune
response actually follows by 7 to 15 days the signs of inflam-
mation detected by CRP elevation and that an increase in
circulating activated T cells and IgM is associated with a more
favorable short-term clinical outcome of UA.
Inflammation in UA. C-reactive protein (3) and IL-6 (2)
are markers of poor short-term clinical outcome in UA. The
present study demonstrates that after the acute phase of
instability, CRP levels decline rapidly, paralleling the resolu-
tion of clinical symptoms but remain elevated in case of an
unfavorable outcome, thus strengthening the hypothesis that
an inflammatory process is associated with the unstable phase
of angina.
Signs of inflammation can be detected both locally in the
culprit lesions and systemically in the circulating blood of UA
patients. The local activation of inflammatory cells could be
due to plaque complication or may, in turn, facilitate plaque
disruption (7,9,19). The systemic inflammatory response may
also be either cause or consequence of endothelial activation
with increased expression of procoagulant and vasoconstrictor
Figure 5. IL-2 levels were similar in unstable and stable angina on
admission, but showed a significant and transient increase at sample 2
only in group A (p , 0.001 vs. samples 1 and 3). Such a time variation
was absent in groups B. The x-axis represents the time of sampling: 1 5
admission; 2 5 after 7 to 15 days; 3 5 after 6 months; A1 5 resolving
UA, n 5 19; A2 5 refractory UA, n 5 16; B1 5 stable angina,
Canadian class I to II, n 5 20; B2 5 stable angina, Canadian class III
to IV, n 5 15.
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substances (20–22). Reperfusion damage following severe,
prolonged ischemia (23) and clot system activation (24,25) may
lead to cytokine release and to an increase in levels of acute
phase reactants. Yet we found that neither ischemia-
reperfusion injury (11) nor activation of the clot-system (10) by
themselves elicit the acute phase response in UA, and indeed
CRP and IL-6 values often remain elevated up to 3 months
after hospital discharge. Thus, inflammation in UA does not
appear to be a consequence of ischemia-reperfusion or throm-
bosis but its trigger is still unclear.
Figure 6. Scatter plot shows the relation between CRP
acute levels (at sample 1) and the percentage increment
in CD31/DR1 (at sample 2 compared to sample 1 in
each patient) in UA (group A). Serum levels of CRP in
the acute phase of UA were inversely related to the
percentage increment of CD31/DR1 lymphocytes at 7
to 15 days (Spearman’s rank correlation: r 5 0.63, p 5
0.0003). Patients with a more favorable outcome
(group A1, open squares) had lower CRP levels and a
higher CD31/DR1 increment as compared with pa-
tients with a less favorable outcome of UA (group A2,
solid squares).
Table 1. Inflammatory and Immune Markers in UA vs. CSA
Group
Time
A B
1 2 3 1 2 3
CRP 7.5 5.5 3.2 3.2 2.4 2.1
(mg/l) (0.4–97.2) (0.2–32.2) (0.2–26.5) (0.4–6.1) (0.4–10.0) (0.4–5.0)
IgG 1,130 1,342 1,320 1,310 12,050 1,230
(mg/dl) (902–1,860) (960–2,620) (965–2,100) (925–1,740) (938–1,870) (965–1,620)
IgA 341 430 399 346 342 360
(mg/dl) (88–569) (152–725) (165–659) (222–621) (199–632) (200–642)
IgM 202 312 198 113 115 120
(mg/dl) (69–618) (112–615) (85–527) (53–613) (43–710) (49–699)
C3 98.7 101.0 103.0 97.9 93.2 99.0
(mg/dl) (59.5–145.0) (80.0–159.0) (76.0–166.0) (55.2–162.0) (54.0–172.3) (52.0–178.0)
C4 39.8 42.0 42.5 42.3 40.3 39.8
(mg/dl) (14.9–89.0) (18.5–89.6) (17.2–93.0) (18.2–94.7) (22.0–100.0) (20.3–99.6)
CD41 52 50 45 42 42 42
(%) (28–65) (24–64) (25–65) (31–54) (29–53) (35–52)
CD81 29 35 32 35 34 32
(%) (13–56) (16–52) (20–53) (25–62) (25–60) (25–58)
IL-2 13.6 44.0 0.1 8.7 7.9 10.0
(pg/ml) (0.0–51.1) (0.0–154.4) (0.0–65.9) (0.0–75.2) (0.0–70.0) (0.0–72.0)
CD31/DR1 5 10 5 5 5 5
(%) (2–9) (3–31) (2–15) (1–16) (2–11) (2–10)
Data are expressed as median (range).
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Immune system activation in UA. An intriguing hypothesis
is that the inflammatory response observed in UA may be part
of an immune, that is, antigen-directed, process. Histologic
studies have consistently demonstrated an abundance of T
lymphocytes within atherosclerotic lesions, especially at sites of
complicated coronary plaques (8,9). Our study is the first to
assess the time course of systemically detectable inflammatory
markers of the immunologic response during waxing and
waning phases of UA. The initial unstable phase of UA is
associated with an acute phase response, indicated by in-
creased levels of CRP, and waning of the instability is followed
by a transient activation of the immune system, indicated by
increased levels of both humoral (IgM) and cellular (IL-2,
CD31/DR1) immunologic markers. This suggests that the
nature of the inflammatory component in UA may be anti-
genic. Interestingly, we found that a favorable outcome is
associated with a greater increment of IgM titre and CD31/
DR1 cells and with a lower inflammatory response.
A dynamic view of immune factors is essential to establish
the biologic association with clinical events. In the study by
Neri Serneri et al. (13) as well as in our own, the percentage of
circulating CD31/DR1 lymphocytes was transiently in-
creased, 7 days after admission, in most UA patients with
favorable outcome. Considering the statistical association of
the immune response with a better outcome, it is tempting to
speculate that the immune response, in some cases, might
actually favor the waning of instability. Conversely, in our study
population and in previous observations (26,27), the admission
levels of activated T cells were not related to the clinical
outcome at variance with the report by Neri Serneri et al. (13).
This may not be surprising because T-cell activation is a
complex phenomenon not easily interpretable in clinical stud-
ies. The regulation of inflammation and antibody production
are under the control of different subsets of immunocompetent
cells. Most disease-inducing T cells are of the Th1 phenotype
(28) and experimental studies suggest that atherosclerosis may
be accelerated by a Th1 immune response (29). But in several
experimental models, induction of a Th2-type immune re-
sponse is protective (30–35). Possibly, the activated T cells
observed in UA patients with better outcome are of the Th2
“protective” phenotype, although this aspect was not assessed
in the present study.
Putative causes of immune system activation. Transient
activation of T lymphocytes as well as transient production of
IgM antibodies imply a recent antigenic stimulation, but the
culprit antigen(s) in patients with UA are not known. Such
antigen(s) may be either self-modified proteins or infectious
agents. Several autoantigens expressed in atherosclerotic
plaque, including oxidized low-density lipoproteins (36,37) and
heat shock proteins (38), can elicit an immune response. It has
also been reported that infectious agents such as Cp (18,39,40),
cytomegalovirus (41) and Helicobacter pylori (42,43) may be
associated with the risk of ischemic heart disease. Cytomega-
lovirus and H. pylori do not appear to be related to instability
of angina (44,45), while viable Cp has recently been found in
active coronary atherosclerotic lesions (46) and thus this
microorganism might be the target for activated lymphocytes
in the unstable plaques. Nevertheless, the total IgM increase
observed in UA patients in the present study cannot be
ascribed to active Cp infection, considering that no specific
IgM for Cp could be detected in these patients. The specific
IgG for Cp were detectable in more the 60% of both UA and
CSA patients, although UA patients tended to be more
frequently seropositive than CSA patients. Suprisingly, the
highest levels of specific antibodies (titre .1/64) were more
frequently detected in group B and in the subgroup A1
(favorable outcome) of the UA group. However, none of the
patients in the study showed any significant increase of the
specific IgG anti-Cp during the study period. Hence, other
antigens have to be considered as the trigger for the transient
immune response in UA. Indeed, the rise in the total antibody
levels in our study as well as the polyclonal origin of plaque T
cells (47) and the many nonspecific clinical infections that have
been associated with ischemic heart disease (40,48) suggest
that different antigenic stimuli might play a role in different
patients or even in the same patient over time.
Immune system activation in CSA. Evidence for T-cell
activation has been found also in the circulating blood of CSA
patients (49), implying that the inflammatory/immune re-
sponse in UA might be generically related to the atheroscle-
rotic background (50,51). Therefore, we choose to compare
the time course of immune parameters in UA in comparison
with a group of patients with similar coronary atherosclerotic
background (CSA patients). We found that severe effort
angina (group B2) is associated with higher percentage of
CD31/DR1, supporting the hypothesis that the immune
system is associated with the chronic atherosclerotic back-
ground. But, of note, in stable patients the time course of this
marker did not vary over the study period. This observation
suggests that the acute and transient immune system activation
observed in UA cannot be explained by the chronic athero-
sclerotic background.
Limitations of the study. Surgical trauma may influence
both the acute phase and immune system responses. Ethical
reasons prevented us from delaying revascularization in cases
of refractory angina. However, the immune and inflammatory
effects of surgery last only 24 h (17) while sample 2 was taken
always .7 days after the revascularization. Moreover, in CSA
elective coronary revascularization did not affect the time
course of any inflammatory marker.
Table 2. Specific IgG titre for Cp
Cp Titre
Negative 1/8–1/32 . 1/64
A1 16.7 66.6 16.7
A2 30.7 53.8 7.8
B1 41.7 33.3 25
B2 30.8 46.2 23
Data are expressed as percentage.
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Table 3. Inflammatory and Immune Markers in the 4 Programs’ Subgroups
Subgroup
Time
A1 A2 B1 B2
1 2 3 1 2 3 1 2 3 1 2 3
CRP 4.5 2.6 2.4 25.8 7.8 6.8 3.3 3.2 3.3 2 2 2
(mg/l) (1.6–8.1) (1.8–22.3) (1.6–11.9) (0.4–97.2) (0.2–32.2) (0.2–26.5) (0.4–6.1) (0.4–10) (0.4–5) (2–6) (2–6) (1.9–5)
IgG 1,040 1,210 1,230 1,130 1,390 1,350 1,230 1,230 1,210 1,470 1,350 1,250
(mg/dl) (980–1,860) (1,030–2,620) (1,050–2,100) (900–1,480) (960–1,950) (960–1,820) (920–1,740) (1,000–1,650) (960–1,560) (920–1,740) (930–1,870) (960–1,620)
IgA 320 430 320 352 453 422 400 395 420 288 280 320
(mg/dl) (88–569) (152–599) (165–635) (183–542) (188–725) (190–659) (222–564) (210–554) (220–560) (233–621) (199–632) (200–642)
IgM 230 369 297 192 278 154 105 104 99 125 128 132
(mg/dl) (101–618) (170–615) (102–527) (69–339) (112–530) (85–436) (70–613) (62–710) (72–699) (53–613) (43–710) (49–699)
C3 86 98 100 106 106 117 98 97 100 101 87 99
(mg/dl) (59–127) (142–80) (76–166) (77–145) (81–159) (96–141) (55–162) (54–172) (52–178) (74–120) (68–146) (75–123)
C4 42 40 42 40 46 44 42 41 39 39 36 40
(mg/dl) (133–867) (32–58) (29–93) (32–89) (18–89) (17–86) (18–95) (22–100) (20–100) (18–98) (22–100) (23–100)
CD41 54 54 45 49 50 45 42 42 42 46 45 45
(%) (28–65) (39–61) (41–59) (36–64) (24–64) (25–65) (36–51) (29–51) (35–50) (31–54) (29–53) (36–52)
CD81 27 35 31 32 36 35 33 33 28 37 40 39
(%) (13–42) (16–42) (20–44) (19–56) (19–52) (20–53) (25–48) (25–44) (25–46) (25–62) (27–60) (26–58)
IL-2 16 49 0 12 38 3 5 5 6 13 15 16
(pg/ml) (0–51) (0–72) (0–45) (0–46) (0–154) (0–65) (0–58) (0–46) (0–49) (0–75) (0–70) (0–72)
CD31/DR1 6 20 5 5 7 4 4 4 5 7 8 8
(%) (2–8) (7–31) (2–15) (2–9) (3–13) (2–9) (1–16) (2–9) (2–8) (1–16) (2–11) (2–10)
Data are expressed as median (range).
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Conclusions. Although evidence of inflammation and of
specific immune activation are found both in CSA and UA
patients (52), we have observed that a “dynamic” immune
response is only detectable in UA patients and is associated
with a favorable outcome. The possibility of a causal role for
the immune system in the pathogenesis and/or in the clinical
outcome of UA, if confirmed, would open novel therapeutic
approaches for this syndrome.
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